Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome

Inclusion Criteria: * Metabolic syndrome patient; Presence of 3 or more of the following: * Abdominal obesity (waist circumference): men \> 90cm(36 inch), women \> 80cm(32 inch) * Triglycerides ≥ 150 mg/dL (1.70 mmol/L) * HDL-C: men \< 40 mg/dL (1.04 mmol/L), women \< 50 mg/dL (1.3 mmol/L) * BP ≥130/≥85 mmHg or subject receiving anti-hypertensive treatment * Fasting blood glucose 110 mg dL (6.11 mmol/L) - 125 mg/dL (6.94 mmol.L) * Elevated LDL-C concentrations reported within 4 weeks of visit 1 as follows; * ≥ 130 mg/dL (3.36 mmol/L) to \< 220 mg/dL (5.69 mmol/L) in statin naive subjects (subjects who have not taken any lipid-lowering therapy known to affect LDL-C in the 4 weeks prior to visit 1) * ≥ 100 mg/dL (2.59 mmol/L) to \< 160 mg/dL (4.14 mmol/L) in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1 * Triglyceride levels \< 400 mg/dL (4.52 mmol/L) * Women of childbearing potential should be using a medically acceptable form of chemical or mechanical contraception. Exclusion Criteria: * History of known diabetes mellitus * Use of anti-hyperglycaemic medication. * History of serious or hypersensitivity reactions to HMG-CoA reductase inhibitors, in particular history of myopathy. * No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is \<10%. * History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia). * Active arterial disease such as unstable angina pectoris, myocardial infarction, transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period * Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) \> 1.5 times the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary lead-in phase. * Current active liver disease (alanine aminotransferase \[ALT\] \> 2 x ULN) or severe hepatic impairment. * Unexplained serum CK \>3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc). * Serum creatinine \> 176 umol/L (2.0 mg/dL) * History of alcohol, or drug, abuse or both.